Michael Feely, MD
Rheumatology · Omaha, NENPI 1689794513
Payments from drug & device makers
What this record shows
This record is dominated by education: $144 of the $184 with a category attached, or 78.5%. Johnson & Johnson accounts for 70.7% of it on its own, with 3 other manufacturers making up the rest. That places this record below the midpoint for rheumatology clinicians in NE, where the typical reported total is $784.
Across 5 payments — averaging $36.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$130
- GSK$20
- Boston Scientific$19
- Pfizer$14
Across 8 payments — averaging $11,632 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$49K
- E.r. Squibb & Sons, L.L.C.$44K
What the payments were for
- Consulting fees$2011%
- Food & beverage$1911%
- Education$14479%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 2 | $130 |
| GSK | 1 | $20 |
| Boston Scientific | 1 | $19 |
| Pfizer | 1 | $14 |
How this compares
$184 in reported general payments places this provider in the 30th percentile of 39 rheumatology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 53 | $378,461 |
| Humira PenAdalimumab | 26 | $168,905 |
| Orencia ClickjectAbatacept | 27 | $144,224 |
| SimponiGolimumab | 22 | $135,625 |
| XeljanzTofacitinib Citrate | 17 | $90,429 |
| Humira(Cf) PenAdalimumab | 12 | $83,512 |
| Actemra ActpenTocilizumab | 26 | $71,446 |
| ForteoTeriparatide | 13 | $64,725 |
| Hydroxychloroquine Sulfate | 401 | $17,057 |
| MethotrexateMethotrexate Sodium | 404 | $11,271 |
| Mycophenolate Mofetil | 67 | $4,774 |
| Prednisone | 583 | $3,714 |
| Leflunomide | 59 | $3,487 |
| Sulfasalazine | 93 | $2,362 |
| Diclofenac Sodium | 127 | $2,262 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSimponi | $130 | $135,62522 claims |
| PfizerXeljanz | $14 | $90,42917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 39 rheumatology providers in Nebraska.
Other rheumatology in Omaha
- Abhijeet DanveOmaha$118K
- Jay KenikOmaha$69K
- Lynell KlassenOmaha$68K
- William PalmerOmaha$24K
- Ted MikulsOmaha$23K
- Amandeep RakhraOmaha$12K
- Carolyn CoyleOmaha$6K
- Joseph NahasOmaha$6K
- James OdellOmaha$4K
- Kathryn WildyOmaha$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.